Imbio PHA (4.0.0) vs Zio ECG Utilization Software (ZEUS) System
AI Verdict
Choose Imbio PHA (4.0.0) if…
Choose Imbio PHA if your primary need is to rapidly and objectively assess cardiac structural changes, such as right ventricular dilation, from CT pulmonary angiogram (CTPA) scans. This tool is ideal for aiding in the diagnosis and risk stratification of conditions like pulmonary embolism and hypertension by providing automated measurements and ratios.
View Imbio PHA (4.0.0) →Choose Zio ECG Utilization Software (ZEUS) System if…
Choose the Zio ECG Utilization Software (ZEUS) System if you need to continuously monitor a patient's cardiac electrical activity over an extended period to detect and classify intermittent or paroxysmal arrhythmias. This cloud-based platform is best suited for diagnosing and managing cardiac rhythm disorders that may not be apparent during a standard ECG or brief clinical visit.
View Zio ECG Utilization Software (ZEUS) System →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Imbio PHA (4.0.0) | Zio ECG Utilization Software (ZEUS) System |
|---|---|---|
| Deployment | Cloud (AWS) or On-premise (VMware) or via partners (Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel). | Cloud-based. |
| FDA Status | Yes AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Imbio PHA (4.0.0)Imbio PHA integrates directly with native DICOM tools and workflows, generating annotated DICOM images and PDF reports within existing radiology systems. This seamless integration and rapid, fully-automated assessment minimize disruption to established clinical processes.
Clinical Value
TieBoth tools offer significant, yet distinct, clinical value. Imbio PHA provides critical quantitative measurements from CTPA scans for acute risk stratification in conditions like pulmonary embolism. ZEUS offers continuous, long-term ECG monitoring for the detection and management of cardiac arrhythmias, which can be elusive with episodic monitoring.
Pricing & Value
TieBoth Imbio PHA and ZEUS System explicitly state 'contact for pricing' and do not provide publicly available pricing details. Without transparent pricing information, it is impossible to conduct a meaningful comparison of their value propositions.
Enterprise Readiness
Imbio PHA (4.0.0)Imbio PHA offers flexible deployment options including cloud, enterprise (on-premise), or via partners, which is crucial for large healthcare systems with specific data governance and infrastructure requirements. While ZEUS is HIPAA compliant and FDA cleared with EHR integration, its cloud-only deployment may not suit all enterprise needs.
Innovation
Zio ECG Utilization Software (ZEUS) SystemThe ZEUS System demonstrates greater innovation by combining AI-powered analysis with proprietary wearable biosensors for continuous, long-term ECG data collection. This approach represents a more disruptive shift in cardiac diagnostics by enabling comprehensive monitoring beyond traditional episodic methods.
Support & Docs
Zio ECG Utilization Software (ZEUS) SystemiRhythm (Tool B) provides more comprehensive support, including a specialized 24/7/365 billing team and extensive online resources like user manuals and FAQs for both healthcare professionals and patients. Imbio (Tool A) offers standard phone and email support with defined hours and downloadable user manuals, but lacks the breadth and accessibility of iRhythm's support ecosystem.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Imbio PHA (4.0.0) | Zio ECG Utilization Software (ZEUS) System |
|---|---|---|
| Name | Imbio PHA (4.0.0) | Zio ECG Utilization Software (ZEUS) System |
| Company | Imbio | iRhythm Technologies |
| Description Summary | FDA-cleared AI-powered medical image processing software that automatically measures cardiac structures from CT pulmonary angiogram (CTPA) scans to assess potential right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension. | AI-powered, cloud-based platform that analyzes continuous ECG data from wearable Zio monitors to aid physicians in the diagnosis and management of cardiac arrhythmias. |
| Primary Data Source | CT pulmonary angiogram (CTPA) scans | Continuous ECG data from wearable Zio monitors |
| Key Outputs/Reports | Annotated DICOM images, summary reports in PDF format | Comprehensive end-of-wear reports for physician review |
| Specialties | Cardiology, Pulmonology, Radiology | Cardiology, Family Medicine, Internal Medicine |
Videos
Demos, reviews, and walkthroughs featuring Imbio PHA (4.0.0) and Zio ECG Utilization Software (ZEUS) System.
Frequently Asked Questions
More Comparisons
More matchups featuring Imbio PHA (4.0.0) or Zio ECG Utilization Software (ZEUS) System
Backers
Who funded each tool's parent company.